237 related articles for article (PubMed ID: 11493443)
21. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
Stadtmauer EA
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
[TBL] [Abstract][Full Text] [Related]
22. Current use and future development of gemtuzumab ozogamicin.
Larson RA
Semin Hematol; 2001 Jul; 38(3 Suppl 6):24-31. PubMed ID: 11474494
[TBL] [Abstract][Full Text] [Related]
23. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
Leopold LH; Berger MS; Cheng SC; Cortes-Franco JE; Giles FJ; Estey EH
Clin Adv Hematol Oncol; 2003 Apr; 1(4):220-5. PubMed ID: 16224410
[TBL] [Abstract][Full Text] [Related]
24. Effect of gemtuzumab ozogamicin on acute myeloid leukemia blast cells in vitro, as a single agent and combined with other cytotoxic cells.
Morris KL; Adams JA; Liu JA
Br J Haematol; 2006 Nov; 135(4):509-12. PubMed ID: 17054677
[TBL] [Abstract][Full Text] [Related]
25. Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-gamma1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line.
Cianfriglia M; Mallano A; Ascione A; Dupuis ML
Int J Oncol; 2010 Jun; 36(6):1513-20. PubMed ID: 20428776
[TBL] [Abstract][Full Text] [Related]
26. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy.
Rajvanshi P; Shulman HM; Sievers EL; McDonald GB
Blood; 2002 Apr; 99(7):2310-4. PubMed ID: 11895761
[TBL] [Abstract][Full Text] [Related]
27. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.
Naito K; Takeshita A; Shigeno K; Nakamura S; Fujisawa S; Shinjo K; Yoshida H; Ohnishi K; Mori M; Terakawa S; Ohno R
Leukemia; 2000 Aug; 14(8):1436-43. PubMed ID: 10942240
[TBL] [Abstract][Full Text] [Related]
28. Resistance to spontaneous apoptosis in acute myeloid leukaemia blasts is associated with p-glycoprotein expression and function, but not with the presence of FLT3 internal tandem duplications.
Pallis M; Turzanski J; Grundy M; Seedhouse C; Russell N
Br J Haematol; 2003 Mar; 120(6):1009-16. PubMed ID: 12648071
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.
Takeshita A
Int J Hematol; 2013 Jun; 97(6):703-16. PubMed ID: 23709007
[TBL] [Abstract][Full Text] [Related]
30. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
31. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
Hamann PR; Hinman LM; Hollander I; Beyer CF; Lindh D; Holcomb R; Hallett W; Tsou HR; Upeslacis J; Shochat D; Mountain A; Flowers DA; Bernstein I
Bioconjug Chem; 2002; 13(1):47-58. PubMed ID: 11792178
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia.
Roboz GJ; Knovich MA; Bayer RL; Schuster MW; Seiter K; Powell BL; Woodruff RD; Silver RT; Frankel AE; Feldman EJ
Leuk Lymphoma; 2002 Oct; 43(10):1951-5. PubMed ID: 12481890
[TBL] [Abstract][Full Text] [Related]
33. [Cytocidal effects of gemtuzumab ozogamicin (CMA-676) on CD33-expressing acute myeloid leukemia cells, analysis P-glycoprotein and CD34 expression].
Matsui H; Takeshita A; Naito K; Onishi K; Ono R
Rinsho Ketsueki; 2002 May; 43(5):309-15. PubMed ID: 12096475
[No Abstract] [Full Text] [Related]
34. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.
ten Cate B; Bremer E; de Bruyn M; Bijma T; Samplonius D; Schwemmlein M; Huls G; Fey G; Helfrich W
Leukemia; 2009 Aug; 23(8):1389-97. PubMed ID: 19262596
[TBL] [Abstract][Full Text] [Related]
35. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype.
Pallis M; Turzanski J; Higashi Y; Russell N
Leuk Lymphoma; 2002 Jun; 43(6):1221-8. PubMed ID: 12152989
[TBL] [Abstract][Full Text] [Related]
36. [Antibody directed therapy for leukemia].
Takeshita A; Naito K; Ohno R
Nihon Rinsho; 2002 Mar; 60(3):517-24. PubMed ID: 11904967
[TBL] [Abstract][Full Text] [Related]
37. Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells.
Rutella S; Bonanno G; Procoli A; Mariotti A; Lucia MB; Contemi AM; Cauda R; Fianchi L; Scambia G; Pagano L; Leone G
Exp Hematol; 2006 Jan; 34(1):54-65. PubMed ID: 16413391
[TBL] [Abstract][Full Text] [Related]
38. Induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells.
Yamauchi T; Matsuda Y; Tasaki T; Negoro E; Ikegaya S; Takagi K; Yoshida A; Urasaki Y; Ueda T
Cancer Sci; 2012 Sep; 103(9):1722-9. PubMed ID: 22632031
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
Sievers EL; Larson RA; Stadtmauer EA; Estey E; Löwenberg B; Dombret H; Karanes C; Theobald M; Bennett JM; Sherman ML; Berger MS; Eten CB; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR;
J Clin Oncol; 2001 Jul; 19(13):3244-54. PubMed ID: 11432892
[TBL] [Abstract][Full Text] [Related]
40. In vitro drug resistance in acute myeloid and chronic B-lymphocytic leukaemic blasts and in normal blood and marrow populations.
Baines P; Limaye M; Hoy T; Padua RA; Whittaker J; al-Sabah A; Burnett A
Leuk Res; 1994 Sep; 18(9):683-91. PubMed ID: 7934144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]